Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Epithalon4 residuesAEDGEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Epitalon, Epithalon, Epithalone
Four amino acids. Ala-Glu-Asp-Gly. That sequence is epithalon (also called epitalon), a tetrapeptide studied for over two decades by Vladimir Khavinson's lab in St. Petersburg. His rodent data showed 10 to 15 percent lifespan extension. In 2025, Al-Dulaimi's group independently confirmed telomere elongation in human cell lines for the first time outside Khavinson's own team [1]. No blinded human trial has ever been published. The community uses it anyway, mostly for sleep. Pineal melatonin normalization kicks in within days, and that effect is consistent across hundreds of self-reports on r/peptides and Longecity.
A 2025 paper changed the conversation around this peptide. Al-Dulaimi and colleagues replicated epithalon's telomere elongation effect in human cell lines [1], confirming telomerase upregulation independent of Khavinson's lab for the first time. Epithalon (epitalon, molecular weight 390.35 Da) is a synthetic tetrapeptide modeled after epithalamin, a pineal gland extract. It activates telomerase, the enzyme that adds TTAGGG repeats to chromosome ends. Short telomeres push cells into senescence or death. Restoring telomerase activity, at least in theory, reverses that clock. The practical picture is more complicated. Every published human observation comes from Khavinson's own unblinded cohorts in elderly Russian populations during the 1990s and 2000s. No randomized controlled trial exists. A 2025 IJMS review [2] noted explicitly that safety information on this peptide is missing. Community use tells a different story. Hundreds of users across peptide forums run 10-day cycles twice per year and report rapid sleep improvement, typically by day 3 to 5. That effect operates through pineal melatonin normalization, a faster and better-understood mechanism than telomere extension. Deeper sleep, fewer awakenings, and improved morning energy are the most reproducible outcomes. The telomere claim itself is taken largely on faith since no practical at-home marker exists; telomere testing before and after multiple cycles is the only objective route, and single-measurement variability is large. At roughly $33 to $50 per 10-day cycle, epithalon is one of the cheapest peptides in the longevity space. Epithalon was on the FDA Category 2 list until April 15, 2026. PCAC review begins July 2026. All current supply is research-grade.
Telomeres are repetitive TTAGGG sequences at chromosome tips. They shorten with every cell division. When they get too short, cells stop dividing or die. Telomerase is the enzyme that rebuilds them. Epithalon activates telomerase in cell cultures. Khavinson's 2003 paper [3] demonstrated telomere elongation in human somatic cells treated with the peptide. The 2025 replication by Al-Dulaimi's group confirmed this finding and added a new wrinkle: some cell lines showed ALT (alternative lengthening of telomeres) pathway activation rather than telomerase upregulation [1]. That second pathway is worth watching because ALT is associated with certain cancer types. The sleep effect runs through a separate mechanism. Epithalon stimulates the pineal gland and restores normal melatonin secretion patterns. Goncharova and colleagues showed this in aging primates and rats [4]. Pineal restoration is a much faster biological response than telomere extension; it explains why sleep improves within days while telomere changes, if they occur in living humans, would take months or years to measure. Plasma half-life is estimated at roughly 30 minutes based on tetrapeptide class pharmacokinetics. No formal human PK study has been published. Daily injection maintains exposure through repeated stimulation rather than sustained blood levels. The short-burst cycling protocol (10 days on, months off) follows the logic that telomerase activation triggers a persistent cellular process. You're kickstarting repair, not maintaining a drug level.
Telomerase activation and telomere elongation confirmed in cell cultures (human and bovine). Rodent data shows 10–15% lifespan extension. Al-Dulaimi et al. (2025) is the first independent Western replication: in human cell lines only, not a clinical trial. The only human data comes from Khavinson's own unblinded, uncontrolled observational cohorts in elderly Russian populations (1990s–2000s). A 2025 IJMS systematic overview explicitly noted "information regarding critical issues about this peptide's safety is missing." The mechanism is real. The human proof is not there yet.
Al-Dulaimi et al. (2025): "Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity." Biogerontology. First independent non-Khavinson replication. PMID 40908429 / PMC12411320.
No RCTs. No blinded human trials. No published human pharmacokinetic data. Half-life (~30 min) is an unverified class-level estimate with no published PK source. 2025 replication is in vitro only. Khavinson cohort studies lack blinding, randomization, and independent oversight. ALT pathway activation in cancer cell lines (Al-Dulaimi 2025) is a new, unresolved safety signal.
Widely used in longevity and biohacker communities. Sleep improvement is the most consistently and rapidly reported effect: typically within days 3–5. General well-being and energy also commonly reported during and after cycles. The telomere claim is taken largely on faith since there is no practical at-home marker. Community is split on cancer risk: some avoid it entirely due to the telomerase concern, others cite Khavinson's mouse data showing reduced tumor incidence.
Science and community agree on the telomerase mechanism and the melatonin/sleep effect. Community confidence in human anti-aging outcomes significantly exceeds what the scientific evidence supports. Khavinson's observational cohorts are treated as stronger evidence than their methodology warrants. The sleep effect is real and reproducible but operates through pineal melatonin normalization, a much faster and more modest mechanism than telomere extension. The leap from in vitro telomere data to meaningful human anti-aging benefit is unproven.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mg | Daily |
| Moderate | 10mg | Daily |
| Aggressive | 10mg | Daily |
Reconstitution is straightforward. A 10 mg vial with 2 mL bacteriostatic water gives you 5 mg/mL. For a 10 mg dose, you'd draw 100 units (the full 1 mL) from a standard insulin syringe, but that only gets half the vial. Most people add 1 mL of bac water instead. That gives 10 mg/mL; 100 units equals your full 10 mg dose from one vial. For the 5 mg beginner dose: reconstitute with 2 mL bac water (2.5 mg/mL), draw 100 units (1.0 mL) for 2.5 mg per dose. The vial lasts four doses. Alternatively, reconstitute with 1 mL bac water (10 mg/mL) and draw 50 units (0.5 mL) for 5 mg per dose; the vial lasts two days. Option B matches the beginner protocol dose of 5 mg per day. Swirl gently after adding water. Don't shake. Solution should be clear and colorless; discard if cloudy or you see particles. The thing most beginners miss: you won't feel the anti-aging part working. Sleep and energy are your only real-time feedback. For objective data on telomeres, get a baseline test before your first cycle and retest after 2 to 3 completed cycles using the same lab and assay method. Single-measurement variability is large enough to mislead you otherwise. Store lyophilized powder at room temperature for up to 6 months, or refrigerate for longer shelf life. After reconstitution, refrigerate at 2 to 8 degrees C and use within 3 to 4 weeks.
Run 10-20 day intensive cycles, then off for 4-6 months. Effects persist long after the cycle ends. Most users do 2-3 cycles per year.
Epithalon follows Khavinson's original short-burst cycling logic: 10 days of intensive daily injection, then 4–6 months off. The rationale is that telomerase activation triggers a persistent cellular process (telomere elongation) that continues after the peptide is cleared from plasma: you are kickstarting a repair process, not maintaining a blood level. The melatonin normalization effect also appears to outlast the active cycle by weeks. Continuous daily dosing has no published support and increases cumulative exposure to a telomerase activator, which raises the theoretical cancer risk profile without demonstrable additional benefit.
Or use the universal Peptide Calculator for any peptide.
Expected: Sleep improvement within the first week. Energy and well-being during and post-cycle. Telomere effects, if real, accumulate over multiple cycles over years: not perceptible day-to-day.
Monitor: Telomere length testing (TeloYears, Life Length, RepeatDx) before starting and after 2–3 cycles is the only objective data point on the primary mechanism. Sleep wearable (Oura, Whoop, Apple Watch) is the most practical subjective response tracker.
Entrepreneur & Longevity Pioneer
Peptides are effective when used precisely.
Gather supplies: epithalon vial (10 mg or 25 mg), bacteriostatic water, alcohol swabs, 29 to 31 gauge insulin syringe.
Add bacteriostatic water slowly down the side of the vial. For a 10 mg vial, 1 mL bac water gives 10 mg/mL. For a 25 mg vial, 2.5 mL gives 10 mg/mL.
Do not shake. Solution must be clear and colorless.
For 10 mg at 10 mg/mL concentration: pull 100 units (1 mL) on the insulin syringe. For 5 mg at 5 mg/mL: pull 50 units (0.5 mL).
Abdomen (2 inches from navel) or deltoid are most common. Rotate sites over the 10-day cycle.
Pinch skin, insert needle at a 45-degree angle, inject slowly. Release skin and withdraw.
Evening timing aligns with the melatonin normalization effect.
Use within 3 to 4 weeks.
Most users follow a spring and autumn schedule, two cycles per year.
N/A: reference route used in all published research and community protocols
As a tetrapeptide, epithalon is destroyed by digestive enzymes: oral delivery is not viable. Use 29–31 gauge insulin syringe. Abdomen and deltoid are most common sites. Rotate sites over multi-day cycles.
Higher dose likely needed to compensate for lower mucosal absorption; no evidence-based dose established for this route
Some community reports of nasal spray use (1–2 mg/mL, 2–4 sprays per nostril 2×/day). No published data on intranasal epithalon pharmacokinetics or efficacy. Absorption through nasal mucosa for a tetrapeptide of this size is not validated. Not recommended as primary route.
Complementary anti-aging mechanisms: GHK-Cu targets extracellular matrix repair and gene expression modulation; epithalon targets telomere maintenance. Different biological pathways, no known pharmacokinetic interaction. Most common community longevity pairing.
GHK-Cu 1–2 mg/day SC concurrent with the epithalon active cycle
Part of community "full recovery + longevity" stack. BPC-157 for tissue healing and systemic repair; epithalon for cellular aging. Different mechanisms, widely combined in practice. No published interaction data.
BPC-157 250 mcg 2×/day + epithalon 10 mg/day before bed during active cycle
Also part of the community "kitchen sink" longevity stack (BPC-157 + TB-500 + GHK-Cu + Epithalon). TB-500 for systemic tissue repair and healing; epithalon for telomere maintenance. No published synergy or interaction data.
GH secretagogue for body composition and recovery + epithalon for anti-aging. Both GH output and telomere length decline with age. Commonly paired in longevity-focused community protocols. No interaction or synergy data exists.
Epithalon normalizes endogenous melatonin production via pineal stimulation. Concurrent high-dose exogenous melatonin risks excessive sedation and may blunt the pineal feedback loop epithalon is trying to restore. Low-dose melatonin (0.3 mg) likely acceptable but unnecessary during an active cycle.
Telomerase activation directly opposes oncological treatments that target telomerase in cancer cells (e.g., BIBR 1532, imetelstat). Hard contraindication, not theoretical concern. Also contraindicated in anyone with active cancer for the same mechanistic reason.
Do not combinePricing updated 2026-04-09
The biggest concern with epithalon isn't a side effect you'll feel. It's a theoretical risk you can't observe. Telomerase reactivation is a hallmark of cancer cell immortalization. Khavinson's rodent studies actually showed reduced tumor rates with epithalon, but Al-Dulaimi's 2025 paper found ALT pathway activation in cancer cell lines [1]. That's a new signal. Anyone with active cancer or a cancer history should treat this as a hard stop. A 2025 IJMS systematic overview [2] stated explicitly that "information regarding critical issues about this peptide's safety is missing." The total human safety database is small, uncontrolled, and comes almost entirely from one research group. Published side effects from Khavinson's cohort studies: none reported beyond injection site reactions. That's a limitation of the data, not proof of safety. Unblinded observational studies in elderly populations are not designed to catch adverse events with any rigor. Community-reported effects paint a more complete picture. Injection site redness is common and expected for subcutaneous peptide administration. Rotate between abdomen and deltoid over a 10-day cycle. Redness spreading beyond the immediate injection area or lasting more than 24 hours warrants stopping. Vivid dreams and occasionally nightmares are reported by a minority of users. This tracks with the melatonin mechanism; improved melatonin output alters REM sleep architecture. It usually settles within a few days. Dropping to 5 mg/day helps if dreams become disruptive. Daytime drowsiness can occur, particularly if you're stacking epithalon with exogenous melatonin, magnesium, GABA, or valerian. The combination over-sedates. Reduce the dose or shift injection earlier in the evening. Contraindications: pregnancy or breastfeeding, active cancer or cancer history, known hypersensitivity to any of the four amino acid components, autoimmune conditions (use with medical supervision only), and children or adolescents (no safety data). Immunosuppressant users need close monitoring since epithalon may modulate immune function. Anyone on chemotherapy or anti-telomerase agents (imetelstat, BIBR 1532) faces a direct mechanistic conflict. Stop immediately if any unexplained mass or growth appears. Discontinue if cancer is diagnosed at any point during use. Stop if sleep paradoxically worsens. Do not extend cycles beyond 20 days.
Verify Epithalon dosing and safety with a second opinion
Simple 4-amino-acid chain (Ala-Glu-Asp-Gly) that is inexpensive and straightforward to synthesize. This cuts both ways: reputable vendors can produce high-purity product cheaply, but the low price also makes adulteration or under-dosing economically viable. Epithalon was removed from FDA Category 2 on April 15, 2026, but compounding pharmacy access is not yet available pending PCAC review (July 2026). All current supply remains research-grade with variable quality standards and no FDA reference standard to benchmark against.
| Test | When | Target |
|---|---|---|
| Telomere length test | Before starting (baseline), then after 2–3 completed cycles (~12–18 months) | Directional improvement from personal baseline. Single-point telomere measurements have large inter-test variability; use the same lab and assay method for baseline and follow-up. |
| Sleep tracking (wearable or diary) | Continuously: baseline before cycle, throughout active cycle, and 4–8 weeks post-cycle | Improvement over personal pre-cycle baseline: compare cycle averages, not single nights. Consumer wearables are directionally useful but not clinical-grade. |
| CBC + CMP (basic bloodwork) | Annually if running regular cycles | — |
Only objective data point on the primary claimed mechanism. Optional: for users who want measurable data rather than proceeding purely on faith.
Most practical and reproducible way to gauge subjective response. Deep sleep percentage and sleep efficiency are the key metrics.
General health monitoring. Epithalon has no known effect on standard blood markers, but annual labs are good practice for regular research peptide use.
Initial loading phase. No noticeable external changes. Telomerase activation begins at the cellular level. Some users report improved sleep quality within the first few days due to melatonin normalization.
Mid-cycle. Sleep improvements become more consistent. Subtle increases in energy and mental clarity reported by some users. Telomere elongation processes are underway but not yet measurable.
End of active cycle. Cumulative telomerase activation reaches peak effect. Users commonly note improved sleep architecture, better recovery, and a general sense of well-being.
Effects persist after stopping. Telomere length gains from the active cycle are maintained. Melatonin normalization continues. No injections during this period.
Long-lasting cellular benefits continue. Telomere length can be retested to confirm gains. Plan next 10-20 day cycle. Most protocols call for 2-3 cycles per year.
Days 1 to 3 (Loading Phase): Telomerase upregulation starts at the cellular level, but nothing is visible or measurable yet. The plasma half-life sits around 30 minutes, so daily injections maintain exposure through repeated hits rather than continuous blood levels. Some users notice slightly faster sleep onset by night 2 or 3. Most feel nothing. Days 4 to 7 (Early Response Window): Pineal melatonin production begins normalizing. Goncharova's primate data [4] confirmed epithalon restores circadian melatonin rhythms. Sleep improvement is the most commonly reported effect by this point. Deeper sleep, fewer awakenings, better mornings. A subset of users notice a mild mood lift and increased daytime energy. Vivid dreams hit a minority; mild drowsiness after the evening injection is also melatonin-related and typically fades. Days 8 to 14 (Mid/Late Cycle): Cumulative telomerase activation continues. Whether 10 to 14 days of subcutaneous injection produces measurable telomere elongation in a living human remains unknown. Sleep benefits solidify. General well-being improves. Some users report better skin, though it's hard to separate that from sleeping well. Weeks 3 to 12 (Post-Cycle Persistence): No injections. Telomere gains, if they occurred, are maintained since telomeres don't shorten overnight. Melatonin normalization often persists 4 to 8 weeks based on the pineal restoration mechanism. Formal duration hasn't been studied in humans. Sleep quality gradually returns to baseline. Months 4 to 6 (Inter-Cycle Period): Telomere gains hold steady but aren't progressing. Normal age-related attrition resumes. Subjective benefits have mostly faded. Users who post telomere test results after 2 to 3 annual cycles sometimes show modest improvement, but measurement variability makes single data points unreliable. Time to plan the next cycle.
Telomerase upregulation begins at cellular level. Very short plasma half-life (estimated minutes to ~30 min) means daily dosing maintains exposure via repeated stimulation rather than continuous blood levels. No externally observable changes.
Some users notice slightly improved sleep onset by night 2–3. Most feel nothing yet. Considered the loading window.
Pineal melatonin production may begin normalizing. Animal data (Goncharova et al., PMID 15455041) shows epithalon restores circadian melatonin rhythms in aging primates and rats. Faster biological response than telomere elongation.
Sleep improvement is the most commonly reported effect by this point: deeper sleep, fewer awakenings, waking more refreshed. Subtle mood lift and increased daytime energy reported by a subset. This is the window where most users decide whether "it's working."
Cumulative telomerase activation. Whether 10–14 days of SC injection achieves measurable telomere elongation in a living human is unknown: no human biomarker data published.
Sleep benefits solidify. General sense of well-being and vitality. Some users report improved skin appearance, though hard to separate from sleeping better.
Any telomere gains would be maintained: telomeres do not shorten overnight. Melatonin normalization may persist for weeks based on pineal restoration hypothesis; formal duration not studied in humans.
Sleep benefits often persist 4–8 weeks, then gradually return to baseline. Energy and well-being effects fade over weeks. Users plan next cycle.
Telomere gains, if any occurred, are maintained but not progressing. Normal age-related telomere attrition resumes. No active mechanism.
Most subjective benefits have faded. Some users post telomere test results after 2–3 annual cycles showing modest improvement: anecdotal and subject to high measurement variability.
Source: Estimated from tetrapeptide class PK data; rapid peptidase degradation (Khavinson et al.); no formal human PK study published
Loading the interactive decay curve.
Epithalon is classified as a research chemical in the United States. It has no FDA approval for any indication. The FDA placed epithalon on its Category 2 bulk drug substance list, which prohibited US compounding pharmacies from producing it. On April 15, 2026, HHS removed epithalon from Category 2 along with 11 other peptides. PCAC review begins July 2026. Compounding pharmacy access is not yet available. All current US supply comes from research-grade peptide vendors. Quality varies. Request a COA showing HPLC purity above 98% and mass spectrometry confirmation of 390.35 Da molecular weight. WADA status: not currently listed, but athletes competing in tested events should verify with their governing body. This content is for educational and research purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any research peptide.
Peptide Schedule Research TeamReviewed Apr 20266 Citations
